Sirona Biochem Corp (SRBCF) 0.1477 $SRBCF
Sirona Biochem Initiates Research and Development on New Therapies for Keloid Scars and Acne Vulgar
Marketwired - Mon Apr 18, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company"
announces that its CEO, Dr. Howard Verrico, has approved two new therapeutic projects within the skin care portfolio addressing markets with unmet needs. Research and development will proceed for a novel compound for keloid scars and an acne treatment, each with a potentially favourable efficacy/side-effect-profile. Studies have begun for the keloid scar project with initial results expected in Q4 2016. The development program is being established for the acne program and will commence this quarter. The Company will look to partner the therapeutics after In-Vitro studies.
SBM.VN: 0.185 (-0.005), GALE: 0.41 (-0.01), GSK: 44.51 (+0.11), BMY: 59.68 (-0.35), NVS: 82.28 (-0.06)
Sirona Biochem Begins Cell Preservation Research CollaborationWith Dr. Caigan Du, University of British Columbia
Marketwired - Mon Apr 11, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company" announces that it has entered into a research collaboration with Dr. Caigan Du of the University of British Columbia to study the effects of new compounds, produced by Sirona's subsidiary TFChem, for use in the preservation of red blood cells (RBC) and other cell lines.
SBM.VN: 0.185 (-0.005)
Sirona Biochem Begins Cell Preservation Research Collaboration With Dr. Caigan Du, University of British Columbia
Marketwire Canada - Mon Apr 11, 7:00AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company" announces that it has entered into a research collaboration with Dr. Caigan Du of the University of British Columbia to study the effects of new compounds, produced by Sirona's subsidiary TFChem, for use in the preservation of red blood cells (RBC) and other cell lines.
SBM.VN: 0.185 (-0.005)
Sirona Biochem Selected to Present at BIO-Europe Spring
Marketwired - Mon Mar 21, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company" announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe Spring on April 4, 2016, at 10:00 AM CET at the Kistamässan Convention Center, Stockholm, Sweden.
SBM.VN: 0.185 (-0.005)
Sirona Biochem Invited to Present at Dose of the Valley Conference, San Francisco
Marketwired - Mon Jan 25, 7:01AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces that it has been chosen for a second time, by the Consulate General of Canada, to present at the Dose of the Valley conference on February 9 - 10 in San Francisco, California.
SBM.VN: 0.185 (-0.005)
Sirona Biochem Announces Positive Results With New Glycoproteins for Anti-Aging and Regenerative Medicine
Marketwired - Tue Nov 10, 7:03AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to announce the protective effects of new glycoprotein compounds in human fibroblast studies under the stressed conditions of nutrient deprivation, oxidative stress and ultraviolet (UV) radiation.
SBM.VN: 0.185 (-0.005)
Sirona Biochem Retains Strategic Advisor to Commercialize Glycoproteins
Marketwired - Tue Nov 03, 7:02AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company" is pleased to announce that it has retained Dr. Mason Ross as a strategic advisor to the Company. Mason's role will be primarily to provide strategic advice and an action plan for the Company's glycoprotein project, more specifically, revenue generating opportunities, commercial viability, risks and data gaps.
SBM.VN: 0.185 (-0.005), GSK: 44.51 (+0.11)
Sirona Biochem Presents New Results From Glycoprotein Program at BIO-Europe
Marketwired - Mon Oct 26, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (the "Company" announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe on November 4, 2015, at 10:15 am GMT at the International Congress Centre in Munich, Germany.
SBM.VN: 0.185 (-0.005)
Sirona Announces Warrants Exercised
Marketwired - Mon Sep 28, 3:05PM CDT
September 28, 2015 - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company" is pleased to announce that it has generated a total of $1,024,328 as a result of share purchase warrant exercises of 6,120,800 shares and the share purchase option exercise of 300,000 shares over the past week. The warrants had an expiry date of September 19, 2015.
SBM.VN: 0.185 (-0.005)
Sirona to Attend Cosmetic360 Conference in Paris
Marketwired - Thu Sep 24, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company" announces that it will attend Cosmetic360 in Paris, France, October 15-16, 2015. Cosmetic360 is an innovative trade forum for the cosmetic industry. The conference brings together professionals and industry representatives from all over the world. All facets of the cosmetic industry are represented at the conference including, raw materials, formulation, packaging, testing and analysis, finished products, and distribution. More information on the conference can be found at http://www.cosmetic-360.com/en.
SBM.VN: 0.185 (-0.005)
Sirona Biochem Reaches Major Milestone by Successful Scale-Up of Skin Lightening Compound SBM-TFC-1067
Marketwired - Tue Sep 15, 7:02AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB.DE), (the "Company" is pleased to announce the successful scale-up of its skin lightening compound SBM-TFC-1067 ("1067" .
SBM.VN: 0.185 (-0.005)
Sirona Biochem Appoints German Private Bank Hauck & Aufhauser as Designated Sponsor For Xetra(R)
Marketwired - Fri Sep 11, 11:58AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB.DE), (the "Company" is pleased to announce that the Company's shares have been accepted for continuous trading on the German electronic trading platform Xetra®under the ticker symbol "ZSB.DE". The International Security Identification Number (ISIN) is CA82967M1005.
SBM.VN: 0.185 (-0.005)
Sirona Biochem Initiates Research and Development on New Therapies for Keloid Scars and Acne Vulgar
Marketwired - Mon Apr 18, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company"
announces that its CEO, Dr. Howard Verrico, has approved two new therapeutic projects within the skin care portfolio addressing markets with unmet needs. Research and development will proceed for a novel compound for keloid scars and an acne treatment, each with a potentially favourable efficacy/side-effect-profile. Studies have begun for the keloid scar project with initial results expected in Q4 2016. The development program is being established for the acne program and will commence this quarter. The Company will look to partner the therapeutics after In-Vitro studies. SBM.VN: 0.185 (-0.005), GALE: 0.41 (-0.01), GSK: 44.51 (+0.11), BMY: 59.68 (-0.35), NVS: 82.28 (-0.06)
Sirona Biochem Begins Cell Preservation Research CollaborationWith Dr. Caigan Du, University of British Columbia
Marketwired - Mon Apr 11, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company"
announces that it has entered into a research collaboration with Dr. Caigan Du of the University of British Columbia to study the effects of new compounds, produced by Sirona's subsidiary TFChem, for use in the preservation of red blood cells (RBC) and other cell lines. SBM.VN: 0.185 (-0.005)
Sirona Biochem Begins Cell Preservation Research Collaboration With Dr. Caigan Du, University of British Columbia
Marketwire Canada - Mon Apr 11, 7:00AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company"
announces that it has entered into a research collaboration with Dr. Caigan Du of the University of British Columbia to study the effects of new compounds, produced by Sirona's subsidiary TFChem, for use in the preservation of red blood cells (RBC) and other cell lines. SBM.VN: 0.185 (-0.005)
Sirona Biochem Selected to Present at BIO-Europe Spring
Marketwired - Mon Mar 21, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company"
announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe Spring on April 4, 2016, at 10:00 AM CET at the Kistamässan Convention Center, Stockholm, Sweden. SBM.VN: 0.185 (-0.005)
Sirona Biochem Invited to Present at Dose of the Valley Conference, San Francisco
Marketwired - Mon Jan 25, 7:01AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces that it has been chosen for a second time, by the Consulate General of Canada, to present at the Dose of the Valley conference on February 9 - 10 in San Francisco, California.
SBM.VN: 0.185 (-0.005)
Sirona Biochem Announces Positive Results With New Glycoproteins for Anti-Aging and Regenerative Medicine
Marketwired - Tue Nov 10, 7:03AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to announce the protective effects of new glycoprotein compounds in human fibroblast studies under the stressed conditions of nutrient deprivation, oxidative stress and ultraviolet (UV) radiation.
SBM.VN: 0.185 (-0.005)
Sirona Biochem Retains Strategic Advisor to Commercialize Glycoproteins
Marketwired - Tue Nov 03, 7:02AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company"
is pleased to announce that it has retained Dr. Mason Ross as a strategic advisor to the Company. Mason's role will be primarily to provide strategic advice and an action plan for the Company's glycoprotein project, more specifically, revenue generating opportunities, commercial viability, risks and data gaps. SBM.VN: 0.185 (-0.005), GSK: 44.51 (+0.11)
Sirona Biochem Presents New Results From Glycoprotein Program at BIO-Europe
Marketwired - Mon Oct 26, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (the "Company"
announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe on November 4, 2015, at 10:15 am GMT at the International Congress Centre in Munich, Germany. SBM.VN: 0.185 (-0.005)
Sirona Announces Warrants Exercised
Marketwired - Mon Sep 28, 3:05PM CDT
September 28, 2015 - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company"
is pleased to announce that it has generated a total of $1,024,328 as a result of share purchase warrant exercises of 6,120,800 shares and the share purchase option exercise of 300,000 shares over the past week. The warrants had an expiry date of September 19, 2015. SBM.VN: 0.185 (-0.005)
Sirona to Attend Cosmetic360 Conference in Paris
Marketwired - Thu Sep 24, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company"
announces that it will attend Cosmetic360 in Paris, France, October 15-16, 2015. Cosmetic360 is an innovative trade forum for the cosmetic industry. The conference brings together professionals and industry representatives from all over the world. All facets of the cosmetic industry are represented at the conference including, raw materials, formulation, packaging, testing and analysis, finished products, and distribution. More information on the conference can be found at http://www.cosmetic-360.com/en. SBM.VN: 0.185 (-0.005)
Sirona Biochem Reaches Major Milestone by Successful Scale-Up of Skin Lightening Compound SBM-TFC-1067
Marketwired - Tue Sep 15, 7:02AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB.DE), (the "Company"
is pleased to announce the successful scale-up of its skin lightening compound SBM-TFC-1067 ("1067" . SBM.VN: 0.185 (-0.005)
Sirona Biochem Appoints German Private Bank Hauck & Aufhauser as Designated Sponsor For Xetra(R)
Marketwired - Fri Sep 11, 11:58AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB.DE), (the "Company"
is pleased to announce that the Company's shares have been accepted for continuous trading on the German electronic trading platform Xetra®under the ticker symbol "ZSB.DE". The International Security Identification Number (ISIN) is CA82967M1005. SBM.VN: 0.185 (-0.005)
